GlassScriptPhysician profile
Eugene Jonathan Wyszynski
NPI 1760431845
$12,690.53
in general payments reported to CMS, 2019-2025
62 companies · $228 in 2025
The $228 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,715 · 2020: $1,465 · 2021: $2,762 · 2022: $3,324 · 2023: $781 · 2024: $415 · 2025: $228.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $830 · Education: $428 · Long Term Medical Supply Or Device Loan: $167.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $829.61 |
| Education | $427.85 |
| Long Term Medical Supply Or Device Loan | $166.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,381.84 | 2019-2024 | |
| Janssen Biotech, INC. | $1,998.58 | 2019-2025 | Rybrevant, Talvey, Darzalex |
| Incyte Corporation | $926.44 | 2019-2024 | Jakafi |
| Pfizer INC. | $657.40 | 2019-2023 | |
| Amgen INC. | $600.03 | 2019-2022 | |
| Astellas Pharma US INC | $529.30 | 2019-2022 | |
| Eisai INC. | $486.67 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $471.43 | 2019-2022 | |
| Deciphera Pharmaceuticals INC. | $455.21 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $430.72 | 2019-2023 | Yervoy |
| Astrazeneca Pharmaceuticals LP | $287.96 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $242.30 | 2019-2022 | |
| Blueprint Medicines Corporation | $164.08 | 2021-2023 | |
| Octapharma USA, INC. | $162.87 | 2019-2023 | Panzyga |
| Pharmacyclics LLC, An Abbvie Company | $151.54 | 2019-2023 | Imbruvica |
Show all 62 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eugene Wyszynski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.